New study demonstrates significant improvement in survival outcomes using Kiyatec’s 3D Predict Glioma test. Greenville, SC, [August 29, 2024] – Kiyatec, leaders in functional precision oncology, today announced the publication…

Founder and Previous CEO Matt Gevaert to Continue as Member of Board of Directors Kiyatec, a leading biotechnology company specializing in 3D cell culture technology, is pleased to announce the…

Kiyatec, a leading functional precision oncology company specializing in 3D cell culture technology and delivering evidence of therapeutic response in the oncology space, is pleased to announce that Mark Capone,…

August 01, 2023 10:00 AM Eastern Daylight Time GREENVILLE, S.C.--(BUSINESS WIRE)--Kiyatec, a leading biotechnology company specializing in 3D cell culture technologies, is pleased to announce the appointment of Eric Perreault to…

June 27th, 2023 – GREENVILLE, S.C. - Kiyatec, the leader in clinically correlated functional precision oncology, and XenoSTART, the worldwide leader in patient derived xenograft model development, have formally announced their ongoing collaboration…

May 23rd, 2023 – GREENVILLE, S.C. - AstraZeneca and Kiyatec, the leader in clinically correlated functional precision oncology, have entered into a multifaceted research agreement to assess therapeutic efficacy of undisclosed preclinical…

GREENVILLE, S.C. — Kiyatec, Inc., the leader in functional precision oncology, today announced a new investment from the venture philanthropy arms of two leading brain tumor patient organizations. The Brain Tumor Investment Fund, an…

GREENVILLE, S.C.-- Kiyatec, the leader in clinically correlated, published functional precision oncology technology, today announced that two abstracts were accepted for poster presentations at the American Association for Cancer Research…

Company is positioned to scale predictive platform’s impact in cancer patient therapy selection and preclinical pharma services. DECEMBER 12, 2022 – Greenville SC -- Kiyatec Inc. announced today a closing…

Unique Partnership Seeks to Advance Precision Medicine Options for Deadly GBM Brain Tumors Shared goal is using high quality live-cell tissue to achieve patient-specific treatment, improved patient outcomes INDIANAPOLIS (October…